

Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

#### **1. PRODUCT AND COMPANY IDENTIFICATION**

Product name	:	Orbifloxacin / Posaconazole / Mometasone Formulation
Manufacturer or supplier's de Company	eta :	ils MSD
Address	:	No. 485 Jing Tai Road Pu Tuo District - Shanghai - China 200331
Telephone	:	+1-908-740-4000
Emergency telephone number	:	86-571-87268110
E-mail address	:	EHSDATASTEWARD@msd.com
Recommended use of the che	em	ical and restrictions on use
Recommended use Restrictions on use	:	Veterinary product Not applicable

#### 2. HAZARDS IDENTIFICATION

#### **Emergency Overview**

Appearance Colour Odour	:	suspension white to off-white odourless
Causes eye irritation. Toxic to	aqu	atic life with long lasting effects.
GHS Classification		
Serious eye damage/eye irri- tation	:	Category 2B
Long-term (chronic) aquatic hazard	:	Category 2
GHS label elements Hazard pictograms	:	¥2
Signal word	:	Warning



Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Hazar	rd statements	: H320 Causes H411 Toxic to	eye irritation. aquatic life with long lasting effects.
Preca	utionary statements		in thoroughly after handling. ease to the environment.
		for several min easy to do. Co	f eye irritation persists: Get medical advice/ at-
		Disposal:	
		P501 Dispose disposal plant.	of contents/ container to an approved waste
•	ical and chemical haz assified based on avai		
-	<b>h hazards</b> es eye irritation.		

#### **Environmental hazards**

Toxic to aquatic life with long lasting effects.

#### Other hazards which do not result in classification

None known.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 50 -< 70
Orbifloxacin	113617-63-3	>= 1 -< 3
Posaconazole	171228-49-2	>= 0.1 -< 0.25
Mometasone	83919-23-7	>= 0.1 -< 0.25

#### 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air.



Versi 4.0	ion	Revision Date: 2024/09/28	-	OS Number: 9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
of water. Remove contaminated clothing and Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reu In case of eye contact : In case of contact, immediately flus for at least 15 minutes. If easy to do, remove contact lens,		:	In case of contact, immediately flush skin with soap and p of water. Remove contaminated clothing and shoes. Get medical attention.		
		, immediately flush eyes with plenty of water nutes. ove contact lens, if worn.			
	If swallowed		:	Get medical atten	NOT induce vomiting. tion.
;		nportant symptoms ects, both acute and	<ul> <li>Rinse mouth thoroughly with water.</li> <li>Causes eye irritation.</li> <li>First Aid responders should pay attention to self-pro and use the recommended personal protective equi when the potential for exposure exists (see section</li> </ul>		
		ion of first-aiders			nmended personal protective equipment
	Notes to physician		:	Treat symptomati	cally and supportively.
5. FII	REFIGH	TING MEASURES			
:	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
	Unsuita media	ble extinguishing	:	None known.	
	Specific fighting	c hazards during fire-	:	Exposure to com	pustion products may be a hazard to health.
	Hazard ucts	ous combustion prod-	:	Carbon oxides	
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	Special for firefi	protective equipment ighters	:		e, wear self-contained breathing apparatus. tective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES



Version 4.0	Revision Date: 2024/09/28		9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
tive	sonal precautions, protec- equipment and emer- icy procedures	:		ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).
Env	vironmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil se of contaminated wash water. should be advised if significant spillages
	thods and materials for tainment and cleaning up	:	For large spills, pr ment to keep mate be pumped, store Clean up remainin bent. Local or national r posal of this mate employed in the c mine which regula Sections 13 and 1	absorbent material. Tovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. In a materials from spill with suitable absor- regulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- ations are applicable. 5 of this SDS provide information regarding tional requirements.

#### 7. HANDLING AND STORAGE

Handling	
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	<ul> <li>Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the environment.</li> </ul>
Avoidance of contact	: Oxidizing agents
Storage	
Conditions for safe storage	: Keep in properly labelled containers. Keep tightly closed.

\_



### Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
		Store in acco	rdance with the particular national regulations.
Mater	rials to avoid		with the following product types:
Packa	aging material	: Unsuitable m	aterial: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	TWA (Inhal- able particu- late matter)	5 mg/m3	ACGIH
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Posaconazole	171228-49-2	TWA	300 µg/m3 (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	ation: Skin		
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

Engineering measures :	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the poten- tial exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.
------------------------	--

#### Personal protective equipment

Respiratory protection :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.
Filter type :	Combined particulates and organic vapour type
Eye/face protection :	Wear safety glasses with side shields or goggles.
	If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a
	potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection :	Work uniform or laboratory coat.
	Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.



Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06	

	Use appropriate degowning techniques to remove potentially contaminated clothing.
Hand protection	
Material	: Chemical-resistant gloves
Remarks Hygiene measures	<ul> <li>Consider double gloving.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work- ing place.</li> <li>When using do not eat, drink or smoke.</li> <li>Wash contaminated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the</li> </ul>

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available

### **SAFETY DATA SHEET** according to GB/T 16483 and GB/T 17519



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	Not applicable

#### **10. STABILITY AND REACTIVITY**

Reactivity Chemical stability Possibility of hazardous reac- tions	: :	Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products	::	None known. Oxidizing agents No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation	
	Skin contact Ingestion	
	Eye contact	

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity



sion	Revision Date: 2024/09/28	-	OS Number: 9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06		
				significant adverse effects were reported oserved at this dose.		
Acute	dermal toxicity	:	: LD50 (Rat): > 2,000 mg/kg Remarks: No significant adverse effects were reporte			
<u>Com</u>	oonents:					
White	e mineral oil (petroleum	ו):				
Acute	oral toxicity	:	LD50 (Rat): > \$	5,000 mg/kg		
Acute	inhalation toxicity	:	LC50 (Rat): > Exposure time Test atmosphe Assessment: T tion toxicity	: 4 h		
Acute	dermal toxicity	:	LD50 (Rabbit): Assessment: T toxicity	> 2,000 mg/kg he substance or mixture has no acute dern		
Orbif	loxacin:					
Acute	oral toxicity	:	- ( - )	3,000 mg/kg nortality observed at this dose.		
				: > 2,000 mg/kg nortality observed at this dose.		
			LD50 (Dog): >			
			Symptoms: Vo Remarks: No r	miting nortality observed at this dose.		
Acute	inhalation toxicity	:	Remarks: No c	lata available		
Acute	dermal toxicity	:	Remarks: No c	lata available		
	toxicity (other routes of nistration)	:	LD50 (Rat): > 2 Application Ro	200 mg/kg ute: Intramuscular		
			LD50 (Mouse): Application Ro	: 500 mg/kg ute: Intramuscular		
			LD50 (Rat): 23 Application Ro	3 mg/kg ute: Intravenous		
			LD50 (Mouse): Application Ro	: 250 mg/kg ute: Intravenous		



Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

#### Posaconazole:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
		LD50 (Mouse): > 3,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg
Mometasone:		
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3.3 mg/l Exposure time: 4 h
		Test atmosphere: dust/mist
		Remarks: No mortality observed at this dose.
		LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h
		Test atmosphere: dust/mist
Acute toxicity (other routes of	:	
administration)		Application Route: Subcutaneous Symptoms: Breathing difficulties
II		

#### Skin corrosion/irritation

Not classified based on available information.

#### Product:

Species	:	Rabbit
Result	:	Mild skin irritation

#### Components:

White mineral oil (petrole	eum):	
Species Result	:	Rabbit
Result	:	No skin irritation
Orbifloxacin:		
Species	:	Rabbit
Species Method Result	:	Draize Test
Result	:	No skin irritation
Posaconazole:		
		Rabbit
Species Result	:	No skin irritation
ivesuit	•	INO SKIII IIIIdiiUII



Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Mom	etasone:		
Spec Resu		: Rabbit : No skin irritatior	ſ
	ous eye damage/eye	irritation	
<u>Prod</u> Spec Resu	ies	: Rabbit : Mild eye irritatic	on
Com	ponents:		
White	e mineral oil (petrole	eum):	
Spec Resu		: Rabbit : No eye irritation	)
Orbif	floxacin:		
Spec Resu Meth	llt	: Rabbit : Mild eye irritatic : Draize Test	on
Posa	iconazole:		
Spec Resu		: Rabbit : Mild eye irritatio	on
Mom	etasone:		
Spec Resu		: Rabbit : No eye irritation	1
Resp	biratory or skin sens	itisation	
	sensitisation	ailable information.	
-	<b>biratory sensitisation</b> classified based on avai		
Prod Test		: Magnusson-Klig	gman-Test



Versier	Devision Deter	000	Number	Data of last issue: 2024/04/00
Version 4.0	Revision Date: 2024/09/28		Number: 13-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
<u>Com</u>	ponents:			
White	e mineral oil (petrole	eum):		
Test			Suehler Test	
	sure routes		kin contact	
Spec			Guinea pig	
Resu	It	: n	egative	
Orbif	loxacin:			
Test	Туре	: N	aximisation Te	est
	sure routes	: C	Dermal	
Spec			Guinea pig	
Resu	lt	: N	lot a skin sens	itizer.
Posa	conazole:			
Test	Tvpe	: N	lagnusson-Klig	aman-Test
	sure routes		kin contact	
Spec		: 0	Guinea pig	
Resu	lt		egative	
Mom	etasone:			
Test	Туре	: N	aximisation Te	est
	sure routes	: C	Dermal	
Spec			Guinea pig	
	ssment		Does not cause skin sensitisation.	
Resu			negative	
Rema	arks			test on guinea pigs showed this substance to
11		D	e a weak skin	sensitiser.
	n cell mutagenicity lassified based on ava	ailable in	formation.	
Com	ponents:			
White	e mineral oil (petrole	um):		
	otoxicity in vitro	-	est Type: In vi	tro mammalian cell gene mutation test
11		_		0

	Result: negative
Genotoxicity in vivo	<ul> <li>Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</li> <li>Species: Mouse</li> <li>Application Route: Intraperitoneal injection</li> <li>Method: OECD Test Guideline 474</li> <li>Result: negative</li> <li>Remarks: Based on data from similar materials</li> </ul>

#### Orbifloxacin:

### **SAFETY DATA SHEET** according to GB/T 16483 and GB/T 17519



Version 4.0	Revision Date: 2024/09/28		S Number: 9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Geno	otoxicity in vitro	:	Test Type: Ba Result: equivo	icterial reverse mutation assay (AMES) ocal
			Test Type: Mo Result: positiv	ouse Lymphoma /e
				rromosomal aberration Human lymphocytes re
Geno	otoxicity in vivo	:	Species: Mou Cell type: Bor	e marrow pute: Intraperitoneal injection
			Test Type: un Species: Rat Cell type: Live Application Ro Result: negati	oute: Oral
	n cell mutagenicity - ssment	:	Weight of evic cell mutagen.	lence does not support classification as a germ
Posa	conazole:			
Geno	otoxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
			Test Type: Ch Result: negati	rromosomal aberration ve
Geno	otoxicity in vivo	:	Species: Mou Cell type: Bor	e marrow oute: Intravenous
Mom	etasone:			
Geno	otoxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
				rromosomal aberration Chinese hamster lung cells ve
				romosomal aberration Chinese hamster ovary cells

according to GB/T 16483 and GB/T 17519



### Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

	Result: positive
	Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo :	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
	Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity - : Assessment	Weight of evidence does not support classification as a germ cell mutagen.

#### Carcinogenicity

Not classified based on available information.

#### Components:

#### White mineral oil (petroleum):

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	24 Months
Result	:	negative

#### Orbifloxacin:

Species Application Route Exposure time NOAEL Result	<ul> <li>Rat</li> <li>Oral</li> <li>2 Years</li> <li>200 mg/kg body weight</li> <li>negative</li> </ul>
Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 200 mg/kg body weight
Result	: negative

according to GB/T 16483 and GB/T 17519



# Orbifloxacin / Posaconazole / Mometasone Formulation

VersionRevision Date:SDS Number:Date of last issue: 2024/04/064.02024/09/28439113-00020Date of first issue: 2016/01/06	
--	--

#### Posaconazole:

Species	: Rat
Application Route	: oral (feed)
Exposure time Result Remarks	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.
Species Application Route Exposure time Result	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

#### Mometasone:

Species Application Route Exposure time Dose Result	<ul> <li>Rat</li> <li>Inhalation</li> <li>2 Years</li> <li>0.067 mg/kg body weight</li> <li>negative</li> </ul>
Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

#### **Reproductive toxicity**

Not classified based on available information.

#### Components:

#### White mineral oil (petroleum):

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative
Effects on foetal develop- ment	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative
Orbifloxacin:		
Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body

according to GB/T 16483 and GB/T 17519



Version 4.0	Revision Date: 2024/09/28	SDS Nu 439113-		Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
		weig Resi	ht ult: No advers	se effects
Effe men	cts on foetal develop- t	Spec Appl Emb Resu verse	cies: Rat ication Route ryo-foetal to ult: No terato	kicity: LOAEL: 333 mg/kg body weight genic effects, Embryotoxic effects and ad- he offspring were detected only at high ma-
		Spec Appl Gen Emb Resu toxic ed o	cies: Rabbit ication Route eral Toxicity ryo-foetal toy ult: No effects effects and	yo-foetal development e: Oral Maternal: NOAEL: 20 mg/kg body weight kicity: NOAEL: 60 mg/kg body weight s on early embryonic development, Embryo- adverse effects on the offspring were detect- aternally toxic doses, Reduced maternal
		Spec Appl Deve	ult: Effects or	
	roductive toxicity - As- sment		e evidence c al experimer	f adverse effects on development, based on nts.
	aconazole: cts on fertility		Type: Fertilit cies: Rat, ma	y/early embryonic development
		Gen Sym	eral Toxicity	- Parent: NOAEL: 180 mg/kg body weight fects on mating performance
		Spec Gen Sym	cies: Rat, fen eral Toxicity	y/early embryonic development hale - Parent: NOAEL: 45 mg/kg body weight fects on mating performance
Effe	cts on foetal develop- t	Spec Appl Deve	cies: Rat, fen ication Route elopmental T	

according to GB/T 16483 and GB/T 17519



Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Repro	oductive toxicity - As- nent	Species: Rabb Developmenta Result: Fetoto	al Toxicity: LOAEL: 40 mg/kg body weight xicity e of adverse effects on development, based on
II			
	etasone: ts on fertility	Fertility: NOAE Symptoms: Re weight	rtility pute: Subcutaneous EL: 0.015 mg/kg body weight educed embryonic survival, Reduced foetal ects on fertility, Effect on reproduction capacity
Effec ment	ts on foetal develop-	Species: Mous Application Ro Embryo-foetal	abryo-foetal development se bute: Subcutaneous toxicity: LOAEL: 0.06 mg/kg body weight otoxic effects., Teratogenicity and developmen-
		Species: Rat Application Ro Embryo-foetal	nbryo-foetal development oute: Dermal toxicity: LOAEL: 0.3 mg/kg body weight o-foetal toxicity
		Species: Rabb Application Ro Embryo-foetal	
		Species: Rat Application Ro	nbryo-foetal development oute: Subcutaneous toxicity: LOAEL: 0.15 mg/kg body weight s on newborn
		Species: Rabb Application Ro Embryo-foetal	



ersion 0	Revision Date: 2024/09/28	-	9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Repro sessn	oductive toxicity - As- nent	:	animal experim	of adverse effects on development, based or ents., Some evidence of adverse effects on and fertility, based on animal experiments.
	- single exposure assified based on avai	lable	information.	
<u>Com</u>	oonents:			
Momo Rema	<b>etasone:</b> arks	:	Based on avail	able data, the classification criteria are not me
STOT	- repeated exposure			
Not cl	assified based on avai	lable	information.	
<u>Comp</u>	oonents:			
	conazole:			
	sure routes et Organs	÷	Ingestion Adrenal gland.	Bone marrow, Kidney, Liver, Reproductive
	ssment	:	organs, Nervou	
Mome	etasone:			
	sure routes	:	inhalation (dus	
	et Organs ssment	:		n, Liver, Kidney, Skin nage to organs through prolonged or repeate
Repe	ated dose toxicity			
Comp	oonents:			
White	e mineral oil (petroleu	<b>m)</b> :		
Speci		:	Rat 160 mg/kg	
	cation Route	:	Ingestion	
Applio Expos	cation Route sure time	:	90 Days	
Applic Expos	cation Route sure time es	:	90 Days Rat	
Applic Expos Speci LOAE	cation Route sure time es :L	:	90 Days Rat >= 1 mg/l	t/mist/fume)
Applic Expos Speci LOAE Applic	cation Route sure time es	:	90 Days Rat	

#### Orbifloxacin:

according to GB/T 16483 and GB/T 17519




Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Expo	EL	: Rat : 20 mg/kg : 80 mg/kg : Oral : 3 Months : Testis, Liver, ł	Kidney, spleen
	EL	: Mouse : 80 mg/kg : 250 mg/kg : Oral : 3 Months	
Expo Targe	EL EL cation Route sure time et Organs otoms	<ul> <li>Juvenile dog</li> <li>50 mg/kg</li> <li>250 mg/kg</li> <li>Oral</li> <li>14 Days</li> <li>Heart, Bone</li> <li>Gastrointestin</li> <li>mortality obse</li> </ul>	
Expo	EL EL cation Route sure time et Organs	: Juvenile dog : 2 mg/kg : 3 mg/kg : Oral : 90 Days : Bone : No significant	adverse effects were reported
Speci NOAI Applie Expos		: Dog : 37.5 mg/kg : Oral : 30 Days	
Speci NOAI LOAE Applie Expo Symp	EL EL cation Route sure time	: Cat : 7.5 mg/kg : 22.5 mg/kg : Oral : 1 Months : Gastrointestin	al disturbance
Speci LOAE Applie Expos		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal gland	, Lungs, Heart, Liver, spleen, Kidney, Ovary

according to GB/T 16483 and GB/T 17519



Version 4.0	Revision Date: 2024/09/28	SDS Number: 439113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Expo		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lympho	Brain, small intestine, Adrenal gland, Spinal id tissue
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrov	v, Adrenal gland, Lymph nodes, Blood
Expo			d, Bone marrow, Kidney, Nervous system, us gland, Testis, lymphoid tissue
Expo		: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastr	ointestinal tract, spleen
Expo		: Monkey : 8 mg/kg : Intravenous : 1 Months : Cardio-vascu	ular system, Lungs, Adrenal gland, Blood
Speci NOAE LOAE Applic Expos	ΞL	: Rat : 0.005 mg/kg : 0.3 mg/kg : Oral : 30 d : Lymph node:	s, Liver, Adrenal gland, Skin, thymus gland
Expo		: Dog : 0.5 mg/kg : Oral : 30 d : Lymph node:	s, Liver, Adrenal gland, Skin, thymus gland
Speci NOAI Applie		: Rat : 0.00013 mg/ : inhalation (de	l ust/mist/fume)





### Orbifloxacin / Posaconazole / Mometasone Formulation

Version 4.0	Revision Date: 2024/09/28		DS Number: 39113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Exposi Target	ure time Organs	:	90 d Adrenal gland, Lu Kidney, Liver, thy	ngs, Lymph nodes, spleen, Bone marrow, mus gland
Specie	S	:	Dog	

•	209
:	0.0005 mg/l
:	inhalation (dust/mist/fume)
:	90 d
:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver
	:

#### Aspiration toxicity

Not classified based on available information.

#### **Components:**

#### Mometasone:

Not applicable

#### Experience with human exposure

#### Components:

Orbifloxacin: Ingestion		vous system effects, Gastrointestinal on change, anaphylaxis, Rash botosensitisation
Posaconazole:	Remarko. May baube p	
Ingestion		adache, Nausea, Vomiting, Fever, Liver Diarrhoea, hypertension, neutropenia,
Mometasone:		
Inhalation	piratory tract infection, s musculoskeletal pain, ir	itis, Headache, pharyngitis, upper res- sinusitis, oral candidiasis, Back pain, mmune system effects, indigestion
Skin contact	: Symptoms: Dermatitis,	Itching
Further information		
Components:		
Mometasone:		
Remarks	: Dermal absorption poss	sible



Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

#### 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

#### Components:

#### White mineral oil (petroleum):

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox- icity)	:	NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l Exposure time: 28 d
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC (Daphnia magna (Water flea)): 1,000 mg/l Exposure time: 21 d
Posaconazole:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic tox- icity)	:	1



rsion )	Revision Date: 2024/09/28		9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Toxici icity)	ty to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 33 Method: OECD To	
	ity to daphnia and other ic invertebrates (Chron- city)	:	Exposure time: 21 Method: OECD To	
	ctor (Chronic aquatic	:	1	
toxicit Toxici	y) ity to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
Mome	etasone:			
Toxici	ty to fish	:	Exposure time: 96	ryllina (Silverside)): 0.11 mg/l 5 h city at the limit of solubility
			Exposure time: 7	n variegatus (sheepshead minnow)): > 5 mg/ d city at the limit of solubility
	ty to daphnia and other ic invertebrates	:	Exposure time: 48 Method: OECD Te	
Toxici plants	ty to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD To	
Toxici icity)	ity to fish (Chronic tox-	:	NOEC (Pimephale mg/l Exposure time: 32 Method: OECD Te	
	ity to daphnia and other ic invertebrates (Chron- city)	:	NOEC (Daphnia r Exposure time: 21 Method: OECD To	

according to GB/T 16483 and GB/T 17519



### Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date: 2024/09/28	SDS Number:	Date of last issue: 2024/04/06
4.0		439113-00020	Date of first issue: 2016/01/06

I	Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic :	100
toxicity) Toxicity to microorganisms :	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
	NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
Persistence and degradability	
Components:	
White mineral oil (petroleum):	
Biodegradability :	Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d
Posaconazole:	
Biodegradability :	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water :	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111
Mometasone:	
Biodegradability :	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water :	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111
Bioaccumulative potential	

Components:

Posaconazole:

### **SAFETY DATA SHEET** according to GB/T 16483 and GB/T 17519



Vers 4.0	ion	Revision Date: 2024/09/28		0S Number: 9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
Bioaccumulation		:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305		
ĺ	Partition coefficient: n- octanol/water		:	log Pow: 4.15	
	Momet	asone:			
	Bioaccı	umulation	:		s macrochirus (Bluegill sunfish) factor (BCF): 107.1 est Guideline 305
	Partition octanol	n coefficient: n- /water	:	log Pow: 4.68	
	Mobilit	y in soil			
	Compo	onents:			
	Posaco	onazole:			
	Distribution among environ- mental compartments		:	log Koc: 5.52	
	Momet	asone:			
	Distribution among environ- mental compartments		:	log Koc: 4.02	
<b>Other adverse effects</b> No data available					
13 <b>[</b>	DISPOS		IS		
10.1					
	Dispos	al methods			
	Waste f	from residues	:		waste into sewer.
	Contarr	ninated packaging	dling site for recycling or disposal.		should be taken to an approved waste han-
14. 1	RANS	PORT INFORMATION			
	Interna	tional Regulations			
	UNRTE	)G			
	UN nun	nber	:	UN 3082	
	Proper	shipping name	:	N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID,
	Class		:	(Mometasone, Po 9	USALUI IAZUIE)
	Packing	g group	:	III	



Versic 4.0	on	Revision Date: 2024/09/28		DS Number: 9113-00020	Date of last issue: 2024/04/06 Date of first issue: 2016/01/06
1	cholo		_	0	
	Labels Environmentally hazardous		:	9 yes	
IATA-DGR					
L	UN/ID No.		:	UN 3082	
Proper shipping name		:	Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)		
C	Class		:	9	
P	Packing group		:		
L	Labels		:	Miscellaneous	
	Packing aircraft)	g instruction (cargo )	:	964	

Packing instruction (passen- ger aircraft) Environmentally hazardous	:	964 yes
<b>IMDG-Code</b> UN number Proper shipping name	:	UN 3082 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **National Regulations**

GB 6944/12268		
UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
		N.O.S.
		(Mometasone, Posaconazole)
Class	:	9
Packing group	:	III
Labels	:	9
Marine pollutant	:	no

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.



Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

#### **15. REGULATORY INFORMATION**

National regulatory informa Law on the Prevention and					
Regulations on Safety Man	-				
Catalogue of Hazardous Che	-	: This product is not li logue of hazardous meets the definition chemicals and its pr termination.	chemicals, but it of hazardous		
Identification of Major Hazard 18218)	Installations for Hazardo	us Chemicals (GB : N	Not listed		
Hazardous Chemicals for Prid SAWS	ority Management under	: Not listed			
Regulations on Labour Pro	tection in Workplaces w	here Toxic Substances	are Used		
Catalogue of Highly Toxic Ch	Catalogue of Highly Toxic Chemicals : Not listed				
	Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals				
China Severely Restricted To and Export	China Severely Restricted Toxic Chemicals for Import : Not listed and Export				
Regulation on the Administ Catalogue and Classification					
Yangtze River Protection La	aw				
This product does not contair	n any dangerous chemica	Is prohibited for inland rive	er transport.		
The components of this pro AICS	oduct are reported in the : not determined	e following inventories:			
DSL	: not determined				
IECSC	: not determined				
16. OTHER INFORMATION					
Revision Date	: 2024/09/28				
Further information Sources of key data used to	: Internal technical da	ata, data from raw material	SDSs, OECD		



Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

compile the Safety Data Sheet

eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

: 8-hour, time-weighted average

Date format	:	yyyy/mm/dd
Full text of other abbreviation		USA. ACGIH Threshold Limit Values (TLV)

#### ACGIH / TWA

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

#### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only



Version	Revision Date:	SDS Number:	Date of last issue: 2024/04/06
4.0	2024/09/28	439113-00020	Date of first issue: 2016/01/06

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN